# ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

> **NCT03485729** · PHASE2 · TERMINATED · sponsor: **Jazz Pharmaceuticals** · enrollment: 27 (actual)

## Conditions studied

- Endometrial Cancer Recurrent

## Interventions

- **DRUG:** Dordaviprone (ONC201)

## Key facts

- **NCT ID:** NCT03485729
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-21
- **Primary completion:** 2023-01-19
- **Final completion:** 2023-01-19
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** This study was terminated due to a change in the Sponsor's corporate priorities. The decision to terminate the study was not based on any safety concerns.
- **Last updated:** 2024-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03485729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03485729, "ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03485729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*